ะ—ะฐะณั€ัƒะทะบะฐ ะฒะธะดะตะพ...

ะะต ัƒะดะฐะปะพััŒ ะทะฐะณั€ัƒะทะธั‚ัŒ ะฒะธะดะตะพ

ะะฐ ะณะปะฐะฒะฝัƒัŽ

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions. $XBI $XENE $MDGL $ALKS Full video:

BiotechTV's profile picture

BiotechTV

10,176 subscribers

13,777 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 8 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

ะšะพะผะผะตะฝั‚ะฐั€ะธะธ: 0

ะะตั‚ ะดะพัั‚ัƒะฟะฝั‹ั… ะบะพะผะผะตะฝั‚ะฐั€ะธะตะฒ

ะ—ะดะตััŒ ะฟะพัะฒัั‚ัั ะบะพะผะผะตะฝั‚ะฐั€ะธะธ ะธะท ะพั€ะธะณะธะฝะฐะปัŒะฝะพะณะพ ะฟะพัั‚ะฐ

ะŸะพั…ะพะถะธะต ะฒะธะดะตะพ

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:
3:49

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026. Full video:

BiotechTV

25,829 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 6 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:
4:00

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:

BiotechTV

12,936 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 8 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:
1:05

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy. See the whole interview here:

BiotechTV

16,344 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 6 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ก๐ฎ๐ซ๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:
3:27

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ก๐ฎ๐ซ๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened. $IDYA $EYPT $OCUL $PVLA $CRVS Full video:

BiotechTV

29,397 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 5 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:
3:18

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

BiotechTV

16,768 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะผะตััั† ะฝะฐะทะฐะด

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ฎ๐ž๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Americas Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers. $AXSM $VIGL $VSTM $CRVS $HRMY Full video:
6:08

๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ ๐“๐ฎ๐ž๐ฌ๐๐š๐ฒ๐ฌ: Mizuho Americas Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers. $AXSM $VIGL $VSTM $CRVS $HRMY Full video:

BiotechTV

13,455 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:
4:48

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:

BiotechTV

17,128 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 7 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

From NYSE: Gameto CEO Dina Radenkovic / Turner talks about running a women's health biotech, the development of Fertilo, work on menopause, and more. Full video:
6:09

From NYSE: Gameto CEO Dina Radenkovic / Turner talks about running a women's health biotech, the development of Fertilo, work on menopause, and more. Full video:

BiotechTV

14,405 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Metsera Inc. CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA. $MTSR Full video:
6:06

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Metsera Inc. CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA. $MTSR Full video:

BiotechTV

10,378 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:
4:58

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

BiotechTV

36,428 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะผะตััั† ะฝะฐะทะฐะด

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:
2:56

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:

BiotechTV

37,136 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:
0:48

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:

BiotechTV

16,621 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!
0:48

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

BiotechTV

20,583 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะผะตััั† ะฝะฐะทะฐะด

New Program Announcement: BioVenture VoiCes with Chris Garabedian. Today we welcome a regular new program on BiotechTV. Chris Garabedian will host the top venture investors in biotech to get their insights on the sector. Watch here in the future:
0:34

New Program Announcement: BioVenture VoiCes with Chris Garabedian. Today we welcome a regular new program on BiotechTV. Chris Garabedian will host the top venture investors in biotech to get their insights on the sector. Watch here in the future:

BiotechTV

16,055 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

โ€œFrom Shakespeare's perspective, tyranny is bad, but anarchy is even worse.โ€ At IPA Academy, Professor Patrick Gray of the University of Austin shares his research about Shakespeare genius and his indelible mark on Western intellectual tradition. Full discussion:
0:37

โ€œFrom Shakespeare's perspective, tyranny is bad, but anarchy is even worse.โ€ At IPA Academy, Professor Patrick Gray of the University of Austin shares his research about Shakespeare genius and his indelible mark on Western intellectual tradition. Full discussion:

Institute of Public Affairs

266,875 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 9 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

How Tom Lee (Thomas (Tom) Lee (not drummer) FundstratDirect.com) is Preparing For Ethereumโ€™s Future ๐Ÿ”ฎ Fundstrat Global Advisorsโ€™ Head of Research Tom Lee, who is chairman of BitMine Immersion Technologies, shares his perspective on Ethereum. He explains how the asset is being leveraged by crypto treasury firms, as well as a growing number of financial institutions.
3:59

How Tom Lee (Thomas (Tom) Lee (not drummer) FundstratDirect.com) is Preparing For Ethereumโ€™s Future ๐Ÿ”ฎ Fundstrat Global Advisorsโ€™ Head of Research Tom Lee, who is chairman of BitMine Immersion Technologies, shares his perspective on Ethereum. He explains how the asset is being leveraged by crypto treasury firms, as well as a growing number of financial institutions.

Decrypt

90,207 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 8 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:
4:12

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐‡๐’๐๐‚ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Jon Norris has published his full-year venture healthcare report today. The report is full of biotech sector insights like raises, exits, and deals. Download the report: #sponsored
2:02

๐‡๐’๐๐‚ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Jon Norris has published his full-year venture healthcare report today. The report is full of biotech sector insights like raises, exits, and deals. Download the report: #sponsored

BiotechTV

18,404 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐“๐ก๐ž ๐’๐ญ๐ฎ๐๐ข๐จ ๐š๐ญ ๐Š๐ž๐ง๐๐š๐ฅ๐ฅ ๐’๐ช๐ฎ๐š๐ซ๐ž: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:
7:30

๐“๐ก๐ž ๐’๐ญ๐ฎ๐๐ข๐จ ๐š๐ญ ๐Š๐ž๐ง๐๐š๐ฅ๐ฅ ๐’๐ช๐ฎ๐š๐ซ๐ž: Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP. Full video:

BiotechTV

11,800 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด